201 related articles for article (PubMed ID: 6547156)
1. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
2. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
3. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
4. [Studies on the radioreceptor assay of TSH: the properties of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease (author's transl)].
Endo K
Nihon Naibunpi Gakkai Zasshi; 1979 Oct; 55(10):1261-74. PubMed ID: 228998
[TBL] [Abstract][Full Text] [Related]
5. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
[TBL] [Abstract][Full Text] [Related]
6. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
Hardisty CA; Fowles A; Munro DS
Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
[TBL] [Abstract][Full Text] [Related]
7. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
Hardisty CA; Talbot CH; Munro DS
Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
[TBL] [Abstract][Full Text] [Related]
8. [The effect of immunosuppressive therapy on the long acting thyroid stimulator (LATS) and the clinical picture in patients with localized myxedema and exophthalmus].
Depisch D; Höfer R; Schatz H
Wien Klin Wochenschr; 1969 Jan; 81(1):8-10. PubMed ID: 5818436
[No Abstract] [Full Text] [Related]
9. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease.
Orgiazzi J; Williams DE; Chopra IJ; Solomon DH
J Clin Endocrinol Metab; 1976 Feb; 42(2):341-54. PubMed ID: 946604
[TBL] [Abstract][Full Text] [Related]
10. The assay of Graves' immunoglobulins: a comparison of different methods.
Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of LATS in a patient with Graves' disease complicated by nephrotic syndrome.
Kajita Y; Miyoshi Y; Hachiya T; Miyazaki T; Yoshimura M; Ijiichi H; Ochi Y
Endocrinol Jpn; 1980 Dec; 27(6):727-32. PubMed ID: 6790269
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema.
Kuzuya N; DeGroot LJ
J Endocrinol Invest; 1982; 5(6):373-8. PubMed ID: 6132943
[TBL] [Abstract][Full Text] [Related]
14. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
[No Abstract] [Full Text] [Related]
15. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
Hardisty CA; Munro DS
Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
[TBL] [Abstract][Full Text] [Related]
16. Comparison of LATS activity and TSH receptor antibody in Graves' disease.
Kajita Y; Nakajima Y; Ishida M; Ura Y; Ochi Y; Miyazaki T; Hachiya T; Ijichi H
Endocrinol Jpn; 1984 Jun; 31(3):369-74. PubMed ID: 6094169
[TBL] [Abstract][Full Text] [Related]
17. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results].
Busnardo B; Accordi F; Debiasi S
Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578
[No Abstract] [Full Text] [Related]
18. [The determination of long-acting thyroid stimulator (LATS) in thyroid diseases].
Depisch D; Höfer R; Schatz H
Wien Z Inn Med; 1968; 49(4):121-30. PubMed ID: 5757238
[No Abstract] [Full Text] [Related]
19. [Significance of long-acting thyroid stimulator. Reflections on the 1st series of results].
Tourneur R; Letonturier P; Sénécal P
Minerva Med; 1974 Mar; 65(19):995-8. PubMed ID: 4406464
[No Abstract] [Full Text] [Related]
20. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
